Oragenics (OGEN) announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio. The partnership aims to utilize advanced AI modeling to identify optimal receptor binding profiles for novel compounds acquired by Oragenics in 2023. Receptor.AI will apply its proprietary computational models to analyze Oragenics’ molecule structures to inform laboratory testing strategy.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN: